bioRxivMolecular BiologyPreprint
Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS Mutations
Andreas DamianouiD, Zhu LiangiD, Frederik Heymann LasseniD, George VereiD, Svenja HesteriD, Philip D. CharlesiD, Adán Pinto-FernándeziD, Alberto Santos-Delgado, Roman Fischer, Benedikt Mathias KessleriD
- Citations
- 3
Abstract
KRAS is a proto-oncogene encoding a small GTPase. Mutations contribute up to 30% of human solid tumours including lung adenocarcinoma, pancreatic and colorectal carcinomas. Most KRAS activating mutations interfere with GTP hydrolysis, essential for its role as a molecular switch, leading to alterations in their molecular environment and oncogenic signalling. Here, APEX-2 proximity labelling was used to profile the molecular environment of wild type and G12D, G13D and Q61H activating mutants of KRAS under both, starvation and stimulation conditions. We demonstrate by quantitative proteomics the presence of known interactors of KRAS including a-RAF and LZTR1, which varied in abundance with wildtype and KRAS mutants. Notably, the KRAS mutations G12D, G13D and Q61H abrogate association with LZTR1. Wildtype KRAS and LZTR1, as part of the CUL3 ubiquitin E3 ligase complex, affect each others protein stability, revealing a direct feedback loop mechanism. KRAS mutations disconnect this regulatory circuit, thereby contributing to oncogenesis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance
T. Ivanisevic, W. Magits, … A. Sablina·bioRxiv·Feb 27, 2024
- Genetic identification of the RAS proteostatic machinery and its failure to regulate oncogenic variants
Johannes W. Bigenzahn, Felix Kartnig, … Giulio Superti‐Furga·bioRxiv·Dec 11, 2025
- Allosteric regulation of switch-II controls K-Ras oncogenicity
M. H. Yang, T. H. Tran, … K. M. Haigis·bioRxiv·Sep 20, 2022
- Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
D. K. Cheng, T. E. Oni, … D. A. Tuveson·bioRxiv·Sep 14, 2020
- Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs
Antonio Cuevas-Navarro, Laura Rodríguez-Muñoz, … Pau Castel·eLifePeer-reviewed·Apr 25, 2022
- Accurate Characterization of the Allosteric Energy Landscapes, Binding Hotspots and Long-Range Communications for KRAS Complexes with Effector Proteins : Integrative Approach Using Microsecond Molecular Dynamics, Deep Mutational Scanning of Binding Energetics and Allosteric Network Modeling
Sian Xiao, Mohammed Alshahrani, … Gennady M. Verkhivker·bioRxiv·Jan 27, 2025